New blood test could spot lung cancer mutations more accurately
NCT ID NCT06595498
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new, ultra-sensitive blood test (NGS) to detect EGFR gene mutations in patients with advanced lung cancer. Researchers will compare it to the current standard test using stored blood samples from 130 patients. The goal is to see if the new method finds more mutations, which could guide personalized treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Plasma-SeqSensei™ Solid Cancer IVD Kit (a blood test)
What this could lead to
If successful, this could provide a more sensitive blood test for lung cancer mutations, helping doctors choose better treatments without invasive biopsies.
What could go wrong
This is an early evaluation study, not a treatment trial. The new test may not prove more accurate than the current standard, and results may not change patient care immediately.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Istituto Oncologico Veneto
Padova, 35128, Italy